# Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

> **NCT05626959** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Fenix Innovation Group** · enrollment: 54 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** NTI164

## Key facts

- **NCT ID:** NCT05626959
- **Lead sponsor:** Fenix Innovation Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-30
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-11-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-11-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626959, "Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05626959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*